Autobio Diagnostics (603658) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 was RMB 992.2 million, a slight decrease of 0.37% year-over-year.

• Net profit attributable to shareholders was RMB 236.4 million, down 12.39% year-over-year.

• Operating cash flow decreased by 11.88% to RMB 146.6 million compared to the same period last year.

Financial highlights

• Total assets at quarter-end were RMB 12.24 billion, down 0.39% from year-end 2025.

• Shareholders’ equity increased by 2.65% to RMB 9.16 billion from year-end 2025.

• Basic and diluted EPS were both RMB 0.41, a 12.77% decrease year-over-year.

• Gross margin improved as cost of sales declined to RMB 331.0 million from RMB 347.9 million year-over-year.

Key financial ratios and metrics

• Weighted average ROE was 2.62%, down 0.47 percentage points year-over-year.

• Operating profit margin declined as total profit fell 13.29% year-over-year.